AstraZeneca: Stifel still a buyer
(CercleFinance.com) - Stifel reiterates its buy rating on AstraZeneca shares with a target price of 12,200 pence (current price about 10,378 pence, -1.
3%).
"The objectives are ambitious," notes the analyst. "Short term, it is about transitioning Soliris into Ultomiris, whereas medium and long term, it is about diversifying away from C5 and expanding, with the objective to become the leader in rare diseases by 2027."
Stifel notes that AstraZeneca is focusing on two main developments. The first is PPH with Strensiq as the current product and ALXN1850 as the next generation product. "While Strensiq should be approaching a blockbuster this year, we were projecting it to be flattish over time, while together with ALXN1850 it is fair to expect sales to double," the analyst adds, who reiterates his buy rating on the stock.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
3%).
"The objectives are ambitious," notes the analyst. "Short term, it is about transitioning Soliris into Ultomiris, whereas medium and long term, it is about diversifying away from C5 and expanding, with the objective to become the leader in rare diseases by 2027."
Stifel notes that AstraZeneca is focusing on two main developments. The first is PPH with Strensiq as the current product and ALXN1850 as the next generation product. "While Strensiq should be approaching a blockbuster this year, we were projecting it to be flattish over time, while together with ALXN1850 it is fair to expect sales to double," the analyst adds, who reiterates his buy rating on the stock.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.